Chicago—A major international trial will investigate whether a cholesteryl ester transfer protein (CETP) inhibitor can reduce cardiovascular risk, researchers announced during the Scientific Sessions of the American Heart Association (AHA) held here in November. The study seeks to determine whether lipid modification with anacetrapib reduces the risk of coronary death, myocardial infarction, or coronary revascularization in patients with established vascular disease who are taking a statin to treat elevated low-density lipoprotein cholesterol (LDL-C).
Graphic Jump Location
A new drug may increase levels of high-density lipoprotein (HDL-C) cholesterol and lower low-density lipoprotein (LDL-C) cholesterol via cholesteryl ester transfer protein inhibition.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
About 16% of general medical patients report that they have palpitations.1 Within...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.